Under the Symbol:
Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy
Wednesday, November 13, 2019 8:30 AM
Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates
SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has named Ian Wendt, an executive who has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry during his 25 years in the sector, to the role of vice president, commercial strategy for both Jaguar and the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
"We're very happy to have appointed Ian to this key role," Lisa Conte, Jaguar's president and CEO, stated. "We believe his broad commercial leadership expertise in the pharmaceutical industry, and in the HIV sector, will play a significant role as we continue to focus on enhancing patient and market access to Mytesi® (crofelemer) for its current FDA-approved indication. Additionally, we expect him to play a pivotal role in driving commercial efforts in the cancer sector if crofelemer receives approval for our primary target follow-on indication, the symptomatic relief of cancer therapy-related diarrhea."
Prior to joining Jaguar, Wendt was at Gilead Sciences in a variety of field leadership and marketing roles in the HIV and hepatitis C therapeutic areas. Most recently, he led strategy and tactical development for a national team focused on policy and protocol development within key HIV treatment and prevention accounts, capacity building, and direct patient education. Wendt was also responsible for Gilead's efforts to increase hepatitis C virus screening and treatment among non-specialist health care practitioners in support of Gilead's market development efforts for a $10 billion brand franchise. Before Gilead, Wendt was at Boehringer Ingelheim, where he led HIV and oncology sales teams across the US, and led commercial operations at Roxane Laboratories, which included sales operations, analytics, incentive compensation, and training. He received a BSc from Acadia University and an MBA from Dalhousie University in Nova Scotia.
"I firmly believe in Jaguar's mission to continue driving commercial growth of Mytesi (crofelemer) for its current approved indication, and to develop and commercialize a broad-based suite of follow-on indications for patient populations in need around the world," Wendt commented. "I am excited to have the opportunity to contribute to the growth and expansion of this innovative company in the months and years to come."
Dial-In Instructions for Conference Call
When: November 14, 2019 at 9 a.m. Eastern Time
Dial-in (US Toll Free): 800-289-0438
Dial-in (International): 323-794-2423
Conference ID number: 3702255
Live webcast on the investor relations section of Jaguar's website (click here)
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 3702255
Replay of the webcast on the investor relations section of Jaguar's website (click here)
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the belief that Wendt's broad commercial leadership expertise in the pharmaceutical industry, and in the HIV sector, will play a significant role as the Company continues to focus on enhancing patient and market access to Mytesi (crofelemer) for its current FDA-approved indication, the expectation that Wendt will play a pivotal role in driving commercial efforts in the cancer sector if crofelemer receives approval for CTD, and the expectation that Jaguar will host a conference call on November 14, 2019. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar Health, Inc.
SOURCE: Jaguar Health, Inc.